TY - JOUR T1 - <em>Thorax</em> editorial by Jenkins and Beasley related to tiotropium respimat JF - Thorax JO - Thorax SP - 782 LP - 782 DO - 10.1136/thoraxjnl-2013-203228 VL - 68 IS - 8 AU - Norbert Metzdorf AU - Christoph Hallmann AU - Bernd Disse Y1 - 2013/08/01 UR - http://thorax.bmj.com/content/68/8/782.1.abstract N2 - We thank Drs Jenkins and Beasley for their comments in the recent editorial regarding tiotropium (SPIRIVA).1 Preceding the Singh et al 2 analysis cited by the authors, Boehringer Ingelheim (BI) had analysed both the tiotropium HandiHaler and Respimat pooled datasets using patient-level data on-treatment as well as including vital status. The results showed a nominally statistically significant reduction for tiotropium HandiHaler and a numerical increase with tiotropium Respimat compared with the respective placebo group for all-cause mortality. These results are adequately reflected in the local SPIRIVA product information (http://www.medicines.org.uk/EMC/searchresults.aspx?term=spiriva&amp;searchtype=QuickSearch) … ER -